The usefulness of His bundle pacing in a heterogeneous population of patients with impaired left ventricular systolic

Rafal Gardas1,2, Krzysztof S Golba3,4, Danuta Loboda3,4

  • 1Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland. rafal.gardas@gmail.com.

Cardiology Journal
|August 23, 2022
PubMed

Insights

His bundle pacing improves heart function in patients with reduced ejection fraction. This study shows His bundle pacing normalizes QRS duration and leads to significant improvements in left ventricular ejection fraction and reverse remodeling.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Cardiac Pacing

Background:

  • His bundle pacing (HBP) preserves physiological ventricular activation.
  • It can normalize wide QRS duration in patients with intraventricular conduction delay (IVCD).

Purpose of the Study:

  • To evaluate the effectiveness of His bundle pacing in patients with reduced left ventricular ejection fraction (LVEF).
  • To assess the impact of HBP on ventricular remodeling and pacing parameters.

Main Methods:

  • 181 patients with LVEF < 50% were enrolled in the study.
  • Indications for HBP included bradycardia, IVCD with resynchronization indication, or pacing-induced cardiomyopathy.
  • Pacing parameters, echocardiographic, and clinical data were assessed up to 24 months.

Main Results:

  • His bundle pacing was successful in 85.1% of patients.
  • At 6-month follow-up, LVEF improved from 35.3% to 43.1% (p < 0.0001).
  • Indexed left ventricular end-systolic volume decreased significantly, with 53.1% showing >15% reduction.

Conclusions:

  • His bundle pacing improves LVEF in permanently paced patients with reduced ejection fraction.
  • HBP is associated with reverse left ventricle remodeling.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
699
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
423
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
39
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.5K
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
25
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
74